Agenda

Day 1 - Monday, April 27, 2015

7:30
Registration & Continental Breakfast
8:30
Opening Remarks from the Conference Co-Chairs
8:45
Interacting with Government Officials in China: Local Experts Discuss the Most Effective Protocols for Dawn Raids, Negotiations, Inquiries and Regulatory Approvals
9:45
Obtaining Information about Employees and Third Parties in China without Violating Local Privacy and State Secret Limits
10:45
Networking Coffee Break
11:00
Where Life Sciences Companies are At Most Risk of Enforcement in China: How SAIC and PSB Decide Which Companies and Individuals to Investigate and Prosecute for Bribery
11:45
Grants, Event Sponsorship and Travel Agencies: How to Track Payments and Detect Bribery Risks through Effective Internal Controls
12:45
Networking Luncheon
2:00
The Biggest FCPA Compliance Weaknesses Found across the Life Sciences Industry: What USDOJ and SEC Now Expect from Pharmaceutical, Biotechnology, Medical Device Companies, and CROs
3:00
Networking Refreshment Break
3:15
CRO Compliance & Internal Controls: CROs and Sponsors Discuss Their Approaches to Managing Pre- and Post-Market Corruption Risks
4:30
The Biggest Customs Clearance Hurdles Facing The Life Sciences Industry: How to Manage Heightened Bribery Risks when Dealing with Customs Officials, Agents and Brokers
5:30
Conference Adjourns

Day 2 - Tuesday, April 28, 2015

8:30
Opening Remarks from the Co-Chairs
8:35
What to Do When Local Customs Conflict with FCPA Requirements: How to Manage High Risk Scenarios Affecting Your Operations, Transactions, Clinical Trials and Local Reporting Obligations
10:00
Networking Coffee Break
10:15
Interactive Discussion And Demonstration – Data Analytics and Automated Controls in Practice: How to Leverage Automation to Improve Compliance and Investigative Outcomes
11:15
Post-M & A Integration: Managing Successor Liability and New Anti-Corruption Compliance Risks Impacting the Life Sciences Industry
12:15
Networking Luncheon
1:30
Auditing Foreign Distributors, Clinical Research, External Field Force and Other Third Parties: How to Audit through Effective Testing and Evaluation of Internal Controls, Books and Records, Policies and Procedures
2:30
The Sunshine Act and the Impact on Global Enforcement: How to Satisfy Reporting Obligations and Assess the Risks Posed by the Disclosed Data
3:15
Networking Refreshment Break
3:30
The Heavy Price of Overlapping Corruption and Economic Sanctions Liability: Dovetailing Your Global Screening and Healthcare Compliance Resources to Reduce Multiple, Cross-Agency Penalty Risks
4:15
Settling Your Case without Risking Debarment and Exclusion from Federal Healthcare Programs: How to Build Your Defense and Showcase Your FCPA Compliance Program to Government
5:15
Main Conference Concludes

Day 1 - Monday, April 27, 2015

7:30
Registration & Continental Breakfast
8:30
Opening Remarks from the Conference Co-Chairs

Brian Howe
Head of Investigations, Compliance and Ethics
Bristol-Myers Squibb

Bret A. Campbell
Partner
Cadwalader, Wickersham & Taft LLP
8:45
Interacting with Government Officials in China: Local Experts Discuss the Most Effective Protocols for Dawn Raids, Negotiations, Inquiries and Regulatory Approvals
9:45
Obtaining Information about Employees and Third Parties in China without Violating Local Privacy and State Secret Limits
10:45
Networking Coffee Break
11:00
Where Life Sciences Companies are At Most Risk of Enforcement in China: How SAIC and PSB Decide Which Companies and Individuals to Investigate and Prosecute for Bribery
11:45
Grants, Event Sponsorship and Travel Agencies: How to Track Payments and Detect Bribery Risks through Effective Internal Controls
12:45
Networking Luncheon
2:00
The Biggest FCPA Compliance Weaknesses Found across the Life Sciences Industry: What USDOJ and SEC Now Expect from Pharmaceutical, Biotechnology, Medical Device Companies, and CROs
3:00
Networking Refreshment Break
3:15
CRO Compliance & Internal Controls: CROs and Sponsors Discuss Their Approaches to Managing Pre- and Post-Market Corruption Risks
4:30
The Biggest Customs Clearance Hurdles Facing The Life Sciences Industry: How to Manage Heightened Bribery Risks when Dealing with Customs Officials, Agents and Brokers

Irina Lazieva
Senior Counsel, CEEMEA Area Compliance Leader
3M Russia

Inga Saltykova
Chief Compliance Officer, Russia/CIS
General Electric
5:30
Conference Adjourns

Day 2 - Tuesday, April 28, 2015

8:30
Opening Remarks from the Co-Chairs
8:35
What to Do When Local Customs Conflict with FCPA Requirements: How to Manage High Risk Scenarios Affecting Your Operations, Transactions, Clinical Trials and Local Reporting Obligations
10:00
Networking Coffee Break
10:15
Interactive Discussion And Demonstration – Data Analytics and Automated Controls in Practice: How to Leverage Automation to Improve Compliance and Investigative Outcomes
11:15
Post-M & A Integration: Managing Successor Liability and New Anti-Corruption Compliance Risks Impacting the Life Sciences Industry
12:15
Networking Luncheon
1:30
Auditing Foreign Distributors, Clinical Research, External Field Force and Other Third Parties: How to Audit through Effective Testing and Evaluation of Internal Controls, Books and Records, Policies and Procedures
2:30
The Sunshine Act and the Impact on Global Enforcement: How to Satisfy Reporting Obligations and Assess the Risks Posed by the Disclosed Data
3:15
Networking Refreshment Break
3:30
The Heavy Price of Overlapping Corruption and Economic Sanctions Liability: Dovetailing Your Global Screening and Healthcare Compliance Resources to Reduce Multiple, Cross-Agency Penalty Risks
4:15
Settling Your Case without Risking Debarment and Exclusion from Federal Healthcare Programs: How to Build Your Defense and Showcase Your FCPA Compliance Program to Government
5:15
Main Conference Concludes